Premium
Cover Feature: 2‐Phenyloxazole‐4‐carboxamide as a Scaffold for Selective Inhibition of Human Monoamine Oxidase B (ChemMedChem 18/2019)
Author(s) -
Di Paolo Maria L.,
Christodoulou Michael S.,
Calogero Alessandra M.,
Pinzi Luca,
Rastelli Giulio,
Passarella Daniele,
Cappelletti Graziella,
Dalla Via Lisa
Publication year - 2019
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201900504
Subject(s) - monoamine oxidase b , carboxamide , monoamine oxidase , chemistry , gene isoform , monoamine oxidase a , feature (linguistics) , monoamine oxidase inhibitor , pharmacology , combinatorial chemistry , neuroscience , stereochemistry , biochemistry , medicine , psychology , gene , enzyme , philosophy , linguistics
The Cover Feature shows the steeplechase of a new promising inhibitor of monoamine oxidase B (MAO‐B), a pharmacological target for the treatment of neurodegenerative disorders, such as Parkinson's disease. The 2‐(2‐hydroxyphenyl)‐ N ‐phenyloxazole‐4‐carboxamide (compound 4a ) participates in the race, jumping over the most important obstacles to become a successful model for the development of novel drugs targeting MAO‐B. The first obstacle is effectiveness as a MAO‐B inhibitor, the second is represented by the selectivity towards the MAO‐B isoform, and the third is the safety for NGF‐differentiated PC12 cells. More information can be found in the Full Paper by Lisa Dalla Via et al. on page 1641 in Issue 18, 2019 (DOI: 10.1002/cmdc.201900261).